Suba Krishnan
Impact in
Papers in
- Co-authors
- Katherine A. Hajjar (2 shared papers)Xiaotao Qu (1 shared paper)Alexandre Lambert (1 shared paper)Matthew D. Galsky (1 shared paper)Sergio Bracarda (1 shared paper)Arlene Odelia Siefker-Radtke (1 shared paper)Marc‐Oliver Grimm (1 shared paper)Andrea Necchi (1 shared paper)
- Journals
- Blood (3 papers)British Journal of Haematology (3 papers)Journal for ImmunoTherapy of Cancer (2 papers)Clinical Chemistry (1 paper)Clinical Biochemistry (1 paper)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Suba Krishnan
19 papers receiving 3k citations
Suba Krishnan's Hit Papers
Peers
Comparison fields: 5 of 71
- Oncology 1.4k
- Genetics 309
- Surgery 1.1k
- Immunology 185
- Cancer Research 69
Countries citing papers authored by Suba Krishnan
This map shows the geographic impact of Suba Krishnan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suba Krishnan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suba Krishnan more than expected).
Fields of papers citing papers by Suba Krishnan
This network shows the impact of papers produced by Suba Krishnan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suba Krishnan. The network helps show where Suba Krishnan may publish in the future.
Co-authors
The 25 scholars most cited alongside Suba Krishnan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2017 | 1382 |
| 2 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies Hit paper breakdown → | 2020 | 391 |
| 3 | 2016 | 349 | |
| 4 | 2019 | 309 | |
| 5 | 2017 | 156 | |
| 6 | 1999 | 141 | |
| 7 | 2021 | 98 | |
| 8 | 2009 | 93 | |
| 9 | 2012 | 64 | |
| 10 | 2011 | 34 | |
| 11 | 2008 | 26 | |
| 12 | 2003 | 19 | |
| 13 | 2016 | 17 | |
| 14 | 1998 | 15 | |
| 15 | 2016 | 11 | |
| 16 | 2009 | 8 | |
| 17 | 1999 | 3 | |
| 18 | 2010 | 2 | |
| 19 | 2009 | 1 |
About Suba Krishnan
Suba Krishnan is a scholar working on Genetics, Oncology, Physiology, Nutrition and Dietetics and Hematology, having authored 19 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), Hemoglobinopathies and Related Disorders (7 papers), Clinical Laboratory Practices and Quality Control (2 papers), Glioma Diagnosis and Treatment (1 paper), TGF-β signaling in diseases (1 paper), Cholangiocarcinoma and Gallbladder Cancer Studies (1 paper), Bladder and Urothelial Cancer Treatments (1 paper) and S100 Proteins and Annexins (1 paper). The work is most often cited by research in Oncology (1.4k citations), Genetics (309 citations), Surgery (1.1k citations), Immunology (185 citations) and Cancer Research (69 citations). Suba Krishnan has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Katherine A. Hajjar, Xiaotao Qu, Alexandre Lambert, Matthew D. Galsky, Sergio Bracarda, Arlene Odelia Siefker-Radtke, Marc‐Oliver Grimm, Andrea Necchi, Daniel A. Vaena and José Ángel Arranz. Their work appears in journals such as Blood, British Journal of Haematology, Journal for ImmunoTherapy of Cancer, Clinical Chemistry and Clinical Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.